160 active not recruiting. 160 Phase 2, 29 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 160 | Active not recruiting 160 |
| Phase 1 | 29 | Active not recruiting 29 |
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) Venetoclax - Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma | Phase 2 | Active not recruiting | AbbVie | 14 | 2026-03-17 | 2026-09-09 |
| A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma JNJ-79635322 - Multiple Myeloma | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 168 | 2026-02-08 | 2026-09-25 |
| Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel Nivolumab - Multiple Myeloma | Phase 2 | Active not recruiting | Wake Forest University Health Sciences | 1 | 2025-02-28 | 2026-07-13 |
| MMRC Horizon One: RRMM (MMRC-099) Teclistamab Monotherapy, Teclistamab - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Active not recruiting | Multiple Myeloma Research Consortium | 300 | 2024-11-17 | 2026-06-05 |
| A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) ALN-6400, Placebo - Hereditary Hemorrhagic Telangiectasia | Phase 1 / Phase 2 | Active not recruiting | Alnylam Pharmaceuticals | 89 | 2024-11-07 | 2026-10-15 |
| A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma Cilta-cel, Talquetamab - Multiple Myeloma | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 11 | 2024-09-16 | 2026-09-25 |
| GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma GR1803 injection - Multiple Myeloma | Phase 2 | Active not recruiting | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 116 | 2024-08-26 | 2026-05-27 |
| A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma Cilta-cel, Talquetamab, Daratumumab - Multiple Myeloma | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 43 | 2024-08-20 | 2026-09-25 |
| Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant Belantamab Mafodotin, Lenalidomide - Plasma Cell Myeloma | Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 4 | 2024-08-19 | 2026-10-16 |
| Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Multiple Myeloma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 58 | 2024-07-23 | 2026-09-25 |
| Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma Teclistamab, Talquetamab, Lenalidomide - Multiple Myeloma | Phase 2 | Active not recruiting | Nantes University Hospital | 103 | 2024-06-26 | 2026-03-17 |
| A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma Linvoseltamab - Smoldering Multiple Myeloma (SMM) | Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 40 | 2024-01-30 | 2026-04-13 |
| Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma Teclistamab, Daratumumab, Lenalidomide - Multiple Myeloma | Phase 2 | Active not recruiting | University Hospital, Lille | 74 | 2023-12-21 | 2026-09-25 |
| Sequential Therapy in Multiple Myeloma Guided by MRD Assessments Dara-VRd intensification, Dara-R maintenance, AHCT intensification, Dara-R maintenance, AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance - Multiple Myeloma | Phase 2 | Active not recruiting | University of Alabama at Birmingham | 300 | 2023-12-13 | 2026-09-22 |
| Isa-Pom-Dex in Elderly/Frail Subjects With RRMM Isatuximab, Pomalidomide, Dexamethasone - Multiple Myeloma, Relapse | Phase 2 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 6 | 2023-12-05 | 2026-06-09 |
| Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes Elranatamab (PF-06863135) - Multiple Myeloma in Relapse | Phase 2 | Active not recruiting | PETHEMA Foundation | 50 | 2023-11-23 | 2026-06-04 |
| A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia Sonrotoclax, Zanubrutinib - Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent | Phase 2 | Active not recruiting | BeOne Medicines | 114 | 2023-10-23 | 2026-10-20 |
| Cevostamab Following CAR T Cell Therapy for RRMM Cevostamab - Relapsed/Refractory Multiple Myeloma | Phase 2 | Active not recruiting | University of Pennsylvania | 30 | 2023-07-11 | 2025-12-18 |
| Elimination of Minimal Residual Disease After Transplant Dexamethasone, Isatuximab, Lenalidomide - Multiple Myeloma | Phase 2 | Active not recruiting | Medical College of Wisconsin | 30 | 2023-06-26 | 2026-10-20 |
| Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia Pirtobrutinib, Venetoclax - Waldenstrom Macroglobulinemia | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 46 | 2023-05-02 | 2026-05-28 |
Showing 20 of 160. Sign in to see all of them.
Multiple Myeloma (143) · Lymphoma (36) · Hematologic Neoplasms (19) · Waldenstrom Macroglobulinemia (17) · Recurrence (10) · Lymphoma, Non-Hodgkin (9) · Lymphoma, B-Cell, Marginal Zone (7) · Neoplasms (7) · Neoplasms, Plasma Cell (7) · Lymphoma, Mantle-Cell (6) · Hodgkin Disease (5) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Lymphoma, Follicular (5) · Myelodysplastic Syndromes (5) · Leukemia (4)
Hemic and Lymphatic Diseases (160) · Cardiovascular Diseases (159) · Hemorrhagic Disorders (159) · Vascular Diseases (159) · Hematologic Diseases (158) · Immune System Diseases (156) · Neoplasms by Histologic Type (156) · Blood Protein Disorders (155) · Immunoproliferative Disorders (155) · Paraproteinemias (155) · Lymphoproliferative Disorders (154) · Neoplasms (150) · Neoplasms, Plasma Cell (150) · Lymphatic Diseases (51)
Dexamethasone (62) · Lenalidomide (38) · daratumumab (36) · Bortezomib (26) · carfilzomib (25) · Calcium Dobesilate (23) · Biopsy (18) · Specimen Handling (17) · Magnetic Resonance Spectroscopy (15) · isatuximab (15) · pomalidomide (14) · Cyclophosphamide (12) · belantamab mafodotin (11) · iberdomide (9) · auricularum (8)
National Cancer Institute (NCI) (32) · Memorial Sloan Kettering Cancer Center (10) · GlaxoSmithKline (6) · M.D. Anderson Cancer Center (6) · Janssen Research & Development, LLC (5) · PETHEMA Foundation (5) · AbbVie (4) · Dana-Farber Cancer Institute (4) · Nantes University Hospital (4) · Mayo Clinic (3) · Celgene (2) · Christian Buske (2) · City of Hope Medical Center (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Massachusetts General Hospital (2)
United States (123) · France (22) · Spain (22) · Germany (16) · Canada (15) · Greece (15) · Australia (14) · Italy (12) · Netherlands (9) · Brazil (7) · Israel (7) · South Korea (7) · China (6) · Japan (6) · Norway (6)
David S Hong (3) · Filip Janku (3) · Andrew J Yee, MD (2) · Christian Buske, MD (2) · Gunjan Shah, MD (2) · Jason J Luke (2) · John L Hays (2) · Kevin M Kalinsky (2) · Omar Nadeem, MD (2) · Aaron S Mansfield (1)
PMID 33357481, PMID 34182226, PMID 35285981, PMID 20385792, PMID 25824111, PMID 26586415, PMID 29567784, PMID 31866281, PMID 32463741, PMID 33048619, PMID 33682447, PMID 33730360, PMID 33785483, PMID 34048681, PMID 34388020, PMID 34398557, PMID 34470049, PMID 34732857, PMID 34826409, PMID 35027656, PMID 35133871, PMID 35138919, PMID 36029527, PMID 36095849, PMID 36209764, PMID 36351402, PMID 36385536, PMID 36529145, PMID 37053535, PMID 37173224, PMID 37322121, PMID 37611156, PMID 37753960, PMID 37930156, PMID 37934000, PMID 37945755, PMID 37971194, PMID 38270219, PMID 38394666, PMID 38591867, PMID 38677302, PMID 38776914, PMID 39345094, PMID 39388024, PMID 39563886, PMID 39576965, PMID 39626297, PMID 39666929, PMID 39693587, PMID 39778168
U10CA180820 (30), 2023 (18), U24CA196172 (17), 2019 (5), 2014 (2), 2017 (2), 2025 (2), P30CA033572 (2), 2016 (1), 2018 (1), P30CA014089 (1), P30CA015083 (1), P30CA022453 (1), P30CA138292 (1), P50CA186781 (1)